[Anticoagulation in old fallers : a common challenge]

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation necessitates long-term anticoagulation to prevent thromboembolic events like stroke.
• Older adults (≥65 years) are at higher risk for falls and subsequent hemorrhagic adverse events.
• Balancing anticoagulation benefits against bleeding risks is crucial in elderly populations.

Purpose of the Study:

• To evaluate the net benefit of anticoagulation in older adults with atrial fibrillation, considering stroke risk reduction versus bleeding risk.
• To determine if the advantages of preventing stroke-related morbidity and mortality outweigh the potential harms of anticoagulation in this demographic.

Main Methods:

• Review of existing literature and clinical guidelines on anticoagulation in atrial fibrillation.
• Analysis of stroke incidence, functional dependency, cognitive decline, quality of life, and mortality data.
• Assessment of hemorrhagic adverse event rates, including those associated with falls.

Main Results:

• Anticoagulation significantly reduces the incidence of stroke and its associated severe consequences.
• Despite an increased risk of falls and bleeding in older adults, the protective effect against stroke remains substantial.
• The overall benefit of anticoagulation in mitigating stroke-related outcomes surpasses the risks of bleeding events.

Conclusions:

• Long-term anticoagulation is recommended for older adults with atrial fibrillation due to superior benefits in stroke risk reduction.
• Clinical decisions should weigh the significant advantages of preventing stroke against the manageable risks of anticoagulation-related bleeding.
• Anticoagulant therapy remains a cornerstone in managing atrial fibrillation for improved long-term health outcomes in the elderly.